Jul 31
|
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
|
Jul 24
|
Vistagen to Present at the BTIG Virtual Biotechnology Conference
|
Jul 15
|
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
|
Jul 3
|
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay
|
Jun 25
|
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
|
Jun 19
|
Vistagen Therapeutics Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
Jun 18
|
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...
|
Jun 17
|
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
|
Jun 12
|
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
|
Jun 2
|
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
|
Feb 20
|
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
|
Feb 15
|
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations
|
Feb 14
|
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...
|
Feb 13
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
|
Feb 13
|
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
|
Feb 12
|
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
|
Oct 11
|
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
|
Oct 9
|
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
|
Oct 9
|
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
|
Sep 24
|
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug
|